J.T. Beck

403 total citations
10 papers, 91 citations indexed

About

J.T. Beck is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, J.T. Beck has authored 10 papers receiving a total of 91 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Genetics. Recurrent topics in J.T. Beck's work include Advanced Breast Cancer Therapies (2 papers), Glioma Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). J.T. Beck is often cited by papers focused on Advanced Breast Cancer Therapies (2 papers), Glioma Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). J.T. Beck collaborates with scholars based in United States, Spain and France. J.T. Beck's co-authors include Victor M. Pérez-Garcı́a, Michael Murek, Philippe Schucht, Juan Belmonte-Beitia, Marek Bodnar, Magdalena Bogdańska, Jordi Rodón, Mona El-Hashimy, Mark Rosenthal and David Mills and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

J.T. Beck

10 papers receiving 87 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.T. Beck United States	5	37	35	34	18	18	10	91
Gaddy Getz United States	2	34 0.9×	20 0.6×	48 1.4×	4 0.2×	11 0.6×	3	118
Rachele Rosati United States	5	16 0.4×	50 1.4×	63 1.9×	2 0.1×	21 1.2×	12	108
Haiying Kong China	3	31 0.8×	26 0.7×	34 1.0×		14 0.8×	5	77
Federica Baldi Italy	3	7 0.2×	57 1.6×	45 1.3×	6 0.3×	41 2.3×	5	140
Stacey Green United States	3	53 1.4×	17 0.5×	31 0.9×		16 0.9×	4	74
Lyndon J. Kim United States	3	50 1.4×	32 0.9×	12 0.4×	3 0.2×	13 0.7×	5	65
Meghan Burke United States	4	29 0.8×	18 0.5×	51 1.5×		13 0.7×	6	117
Megan H. Jagosky United States	5	20 0.5×	65 1.9×	53 1.6×	1 0.1×	17 0.9×	11	118
Bingsong Huang China	7	11 0.3×	18 0.5×	49 1.4×		20 1.1×	12	102
Nandita Barnabas United States	5	16 0.4×	49 1.4×	60 1.8×		36 2.0×	6	119

Countries citing papers authored by J.T. Beck

Since Specialization

Citations

This map shows the geographic impact of J.T. Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.T. Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.T. Beck more than expected).

Fields of papers citing papers by J.T. Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.T. Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.T. Beck. The network helps show where J.T. Beck may publish in the future.

Co-authorship network of co-authors of J.T. Beck

This figure shows the co-authorship network connecting the top 25 collaborators of J.T. Beck. A scholar is included among the top collaborators of J.T. Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.T. Beck. J.T. Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Hamilton, E.P., J.T. Beck, William R. Gwin, et al.. (2022). 204TiP A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC). Annals of Oncology. 33. S220–S220. 1 indexed citations

Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel‐Donnelly, et al.. (2022). Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E). Blood. 140(Supplement 1). 3685–3686. 1 indexed citations

Jabbour, Elias, Paul Koller, Vivian G. Oehler, et al.. (2022). Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood. 140(Supplement 1). 200–202. 9 indexed citations

Wen, Patrick Y., Jordi Rodón, Warren Mason, et al.. (2020). Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 5(4). e000673–e000673. 26 indexed citations

Rugo, Hope S., J.T. Beck, Guy Jérusalem, et al.. (2020). Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results. Cancer Research. 80(16_Supplement). CT108–CT108. 8 indexed citations

Bogdańska, Magdalena, Marek Bodnar, Juan Belmonte-Beitia, et al.. (2017). A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications. Mathematical Biosciences. 288. 1–13. 26 indexed citations

Nemunaitis, John, Zsolt Pápai, H. Léna, et al.. (2015). TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P441–P441. 1 indexed citations

Blumenschein, G. R., Fairooz F. Kabbinavar, Hari Menon, et al.. (2010). Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7528–7528. 14 indexed citations

Gore, M., J.T. Beck, Timothy Eisen, et al.. (2010). Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies.. Journal of Clinical Oncology. 28(15_suppl). 4605–4605. 1 indexed citations

10.

Alberts, D S, et al.. (2007). Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). International Journal of Gynecological Cancer. 17(4). 784–788. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact